To observe the clinical effect of Supplemented MaXing ShiGan Decoction combined acupoint sticking therapy for acute exacerbation chronic obstructive pulmonary diseases(AECOPD). Methods:A total of 120 patients with AECOPD from December 2013 to December 2015 in our Hospitals were selected according to the random distribution. All patients were divided into decoction group and normal group, each group having 60 cases. The normal group patients were given oxygen, cough, asthma and other symptomatic treatment and salmeterol assigned powder, as well as compound isopropyl bromide amine inhalation therapy. On its base, the decoction group was given Supplemented MaXing ShiGan Decoction with acupoint sticking therapy. Enzyme-linked immunosorbent (ELISA) was used to detect the serum tumor necrosis factor alpha (TNF alpha), interleukin 8 (IL-8), and c-reactive protein (CRP) level. The COPD assessment test scores (CAT) was used to assess the disease severity. Followed-up lasted for 6 months, and (1 s total forced expiratory volume (FEV1), lung (FEV), FEV1 / FEV), serum TNF alpha, IL-8, CRP levels and adverse reactions during treatment, and illness severity of all patients with pulmonary function were detected before and after 1, 3, 6 months of the treatment. Results:After treatment, FEV1, FEV, FEV1 / FEV level of decoction group were significantly higher than normal group (P<0.05); serum TNF alpha, IL-8, CRP levels of decoction group were significantly lower than the normal group (P<0.05); after treatment 1, 3, 6 months CAT scores of decoction group were significantly lower than the normal group (P<0.05), no obvious adverse reactions were shown during treatment. Conclusion:Supplemented MaXing ShiGan Decoction combined acupoint sticking therapy has clear effect in AECOPD, by improving the patient’s lung function and inflammatory state, and relieving the disease, which is worthy for further clinical promotion.